Novel Compound SLU-PP-332 Shows Promise Against Colorectal Cancer
SLU-PP-332 PubChem Profile
Background
Colorectal cancer (CRC) remains a significant global health challenge, often characterized by resistance to conventional therapies. The nuclear receptor RORγ (Retinoic acid receptor-related orphan receptor gamma) is increasingly recognized for its crucial role in promoting tumor growth and immune evasion in various cancers, including CRC. Despite its therapeutic potential, there's a critical need for highly selective and potent RORγ inverse agonists to effectively target this pathway in cancer.